Cargando…

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

BACKGROUND: To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS: Observational clinical study was perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waizel, Maria, Todorova, Margarita G., Masyk, Michael, Wolf, Katharina, Rickmann, Annekatrin, Helaiwa, Khaled, Blanke, Björn R., Szurman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442868/ https://www.ncbi.nlm.nih.gov/pubmed/28535756 http://dx.doi.org/10.1186/s12886-017-0471-x

Ejemplares similares

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization
por: Lytvynchuk, Lyubomyr, et al.
Publicado: (2015)

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
por: Plyukhova, Anna A., et al.
Publicado: (2020)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

An Unusual Case of DMEK Graft Loss into the Vitreous and Its Successful Retrieval and Survival
por: Helaiwa, Khaled, et al.
Publicado: (2018)

Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages
por: Rickmann, Annekatrin, et al.
Publicado: (2021)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
por: Schworm, Benedikt, et al.
Publicado: (2020)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
por: Empeslidis, Theodoros, et al.
Publicado: (2019)

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
por: Gale, Richard P, et al.
Publicado: (2020)

Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
por: Providência, Joana, et al.
Publicado: (2018)

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
por: Hirvonen, Liisa M., et al.
Publicado: (2016)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

Temporary iris-lens diaphragm to assist descemet membrane endothelial keratoplasty in aphakic patients
por: Szurman, Peter, et al.
Publicado: (2022)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
por: Tyagi, Pallavi, et al.
Publicado: (2018)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
por: Kanra, Ayse Yagmur, et al.
Publicado: (2018)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Short-Term Outcomes following “Switching” to Monthly Ranibizumab in Neovascular Age-Related Macular Degeneration Showing Insufficient Response to Bimonthly Aflibercept
por: Lee, Jong Suk, et al.
Publicado: (2021)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
por: Makri, Olga E, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ci2nrbc2qjf58jlr4bm1cglp6h